On January 6, 2022 PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box, reported that it will be featured as a presenting company at the H.C. Wainwright BioConnect Conference (Press release, PharmaCyte Biotech, JAN 6, 2022, View Source [SID1234598364]). The Conference is being held virtually on January 10-13, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the presentation, the Chief Executive Officer of PharmaCyte Biotech, Kenneth L. Waggoner, will provide an overview of the Company’s business and product pipeline.

Over 500 corporate presentations and panels are available on-demand from January 10-13, 2022. The pre-recorded presentation by PharmaCyte will be available on Monday, January 10, 2022, on the News & Media tab of PharmaCyte’s website at View Source

PharmaCyte’s presentation will also be available at View Source

Additionally, PharmaCyte will be publishing a press release in the coming weeks to update its shareholders on the progress PharmaCyte has made to lift the clinical hold the U.S. Food and Drug Administration placed on PharmaCyte’s planned Phase 2b clinical trial for the treatment of locally advanced, inoperable pancreatic cancer.

To learn more about PharmaCyte’s pancreatic cancer treatment and how it works inside the body to treat locally advanced, inoperable pancreatic cancer, we encourage you to watch PharmaCyte’s documentary video complete with medical animations at View Source